Global Emergence of Trimethoprim/Sulfamethoxazole Resistance inStenotrophomonas maltophiliaMediated by Acquisition ofsulGenes
Year: 2007
Type: article
Abstract: Trimethoprim/sulfamethoxazole (TMP/SMX) resistance remains a serious threat in the treatment of Stenotrophomonas maltophilia infections.We analyzed an international collection of 55 S. maltophilia TMP/SMX-sensitive (S) (n = 30) and -resistant (R) (n = 25) strains for integrons; sul1, sul2 and dhfr genes; and insertion element common region (ISCR) elements.sul1, as part of a class 1 integron, was detected in 17 of 25 TMP/SMX-R.Nine TMP/SMX-R strains carried sul2; 7 were on large plasmids.Five TMP/SMX-R isolates were positive for ISCR2, and 4 were linked to sul2; 2 others possessed ISCR3.Two ISCR2s were adjacent to floR.Six TMP/SMX-S isolates harbored novel ISCR elements, ISCR9 and ISCR10.Linkage of ISCR3, ISCR9, and ISCR10 to sul2 and dhfr genes was not demonstrated.The data from this study indicate that class 1 integrons and ISCR elements linked to sul2 genes can mediate TMP/SMX resistance in S. maltophilia and are geographically widespread, findings that reinforce the need for ongoing resistance surveillance.N osocomial Stenotrophomonas maltophilia are intrinsi- cally resistant to a plethora of antimicrobial agents that severely limit commonly used empiric standard antimicrobial therapies.S. maltophilia is resistant to many β-lactams, β-lactamase inhibitors, and aminoglycosides (1,2).A recent survey of SENTRY (www.jmilabs.com)Antimicrobial Surveillance Program isolates indicated that the newer fluoroquinolones demonstrated good efficacy; the most active were levofloxacin (6.5% resistance) and gatifloxacin (14.1%) (3).Furthermore, the resistance to the polymyxins (20%-32%) is higher than observed in Pseudomonas aeruginosa (3,4).Because of low resistance levels (≈5%), trimethoprim/sulfamethoxazole (TMP/ SMX) remains the therapy of choice worldwide.A recent study encompassing data from Europe, Latin America, and North America indicates that the level of resistance to TMP/SMX is 3.8%; however, previous studies indicate that the level is higher in Latin America than North America (5,6).Although surveillance studies are few, resistance to TMP/SMX appears to be emerging, and recent in vitro modeling studies have shown that combination therapies of TMP/SMX plus ciprofloxacin and TMP/SMX plus tobramycin exhibit a greater killing capacity then TMP/SMX alone (7,8).S. maltophilia exhibits an array of mechanisms that singularly or collectively contribute to its multidrug resistance status.Intrinsic resistance includes inducible efflux pumps (2) and multiple β-lactamase expression (1) but not mutations in the quinolone resistance-determining region (9).In addition, S. maltophilia can acquire resistance through integrons, transposons, and plasmids (10).Recently, class 1 integrons have been characterized from S. maltophilia strains isolated in Argentina and Taiwan, which indicates that they contribute to TMP/SMX resistance through the sul1 gene carried as part of the 3′ end of the class 1 integron (10).In addition to class 1 integrons, other mobile elements are associated with sul genes.For example, Vibrio cholerae serogroup 0139 is resistant to several antimicrobial agents, including SMX, and it has been recently shown that the sul2 gene was part of a cluster located on a novel genetic Global Emergence of Trimethoprim/Sulfamethoxazole Resistance in Stenotrophomonas maltophilia Mediated by Acquisition of sul Genes
Source: Emerging infectious diseases
Institutions: Cardiff University, JMI Laboratories
Language: English
Subfield: Microbiology (medical)
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
Funder: Cardiff University
OpenAlex ID: W2163206615
